This amendment revises fees for medical devices, therapeutic products, controlled drugs and psychotropic substances, form a poisons licence, Cell, Tissue or Gene Therapy Products (CTGTP), chinese proprietary medicines, cosmetic products, retail pharmacy licence, medical advertisements and sales promotion.